The study conducted by a research team at the University Hospital in Uppsala under the leadership of associate professor Michael Häggman shows that the gene test Prostatype® correctly assesses the aggressiveness of the prostate cancer tumor when you compare gene expression from tissue samples, so-called biopsies, with "fact", i.e., the removed prostate (radical prostatectomy).
The study is now published in The Prostate, a leading peer-reviewed publication aimed at, among others, urologists, and pathologists.
The study "P-score in preoperative biopsies accurately predicts P-score in final pathology at radical prostatectomy in patients with localized prostate cancer" included 71 patients and aimed to compare the results obtained by using the gene test Prostatype® on tissue samples from biopsies before surgery, with "fact", the gene expressions seen in the cancer cells after prostate cancer surgery.
The results of the study are now published in the leading journal The Prostate, a peer-reviewed publication for original studies on prostate diseases with approximately a quarter of a million downloaded articles per year.
Prostate cancer is considered a multifocal disease, i.e., it often contains several different unique tumors. It is extremely important to know that the result you get from the biopsies is not significantly different from what you see after surgery. The study indicates that the P-score obtained today from a single biopsy is representative of the entire patient's prostate tumor (a correlation of 83%) and therefore constitutes a valuable treatment decision support. Together with results from previous studies, the combined data gives indications that Prostatype® can in a clear and valuable way help the healthcare system to more easily and with greater certainty identify the patients who need radical treatment and the patients who do not need to undergo radical treatment, for example surgery.
Pontus Röbeck, urologist and researcher who participated in the study comments on why the result is so important: "A prognostic test like Prostatype® gives the opportunity to predict how a disease develops over time, and how dangerous it will possibly be for the patient. For doctors and patients to dare to trust the results of the test, it is important that with the help of ‘facts’, operated prostate glands, you can see that Prostatype® shows the same results as you get when analyzing the tissue sample before surgery. We do not want our patients to die due to aggressive prostate cancer, while at the same time we do not want to treat patients unnecessarily given the lifelong side effects that often follow a radical treatment.”
The work carried out in Uppsala is one of the few published studies in the field and compared to other studies, the results with Prostatype® are very interesting in terms of the degree of agreement in gene expression between the tissue samples and the operated prostate, which once again confirms Prostatype's® strong performance.
Prostatype Genomics CEO Fredrik Persson comments on the publication:” Of course I want to start by congratulating the authors on the study with Prostatype®. It is gratifying that The Prostate has chosen to publish the study, the results of which have been requested by urologists both in Europe and the USA. The results of the study strengthen Prototype’s scientific footprint and demonstrate real clinical benefit, but it also gives us very positive exposure to our most important customer groups, leading urologists and pathologists on an international level. Prostatype Genomics has a number of similar studies underway in several priority markets, and with this publication interest in Prostatype® will increase even further. The consequence will of course be that more urologists and hospitals will want to try Prostatype®.
Follow the link below to learn more about the study: